Neuromodulation + Cognitive Training for Traumatic Brain Injury
(CONNECT-TBI Trial)
Trial Summary
What is the purpose of this trial?
The CONNECT-TBI Trial aims to develop safe, effective treatments for complex mTBI that improve cognitive functioning. Based on the compelling preliminary data generated by our study team, the objective of this study is to conduct a randomized, double-blinded, sham-controlled Phase II clinical trial of APT-3 combined with rTMS, HD-tDCS, or sham to treat cognitive control deficits in Veterans with complex mTBI and PPCS. At the Baseline Visit, participants will undergo demographic, neuropsychological, behavioral, and quality of life testing. They will also undergo structural MRI to permit modeling of their brain, resting/task-related fMRI to identify the CCN, and pseudocontinuous arterial spin labeling (pCASL) and diffusion tensor imaging (DTI) to assess for other pathologies. They will then be randomized to 16 sessions of APT-3 with concurrent rTMS, HD-tDCS, or sham stimulation delivered to the unique functional left dorsolateral prefrontal cortex (DLPFC), a primary node of the CCN. Lastly, they will repeat all baseline tests, and report on 3- and 6-month recovery levels to establish longevity and stability of subjective benefit. Given that this individualization protocol has never been attempted for cognitive rehabilitation in military mTBI, we expect this trial will generate useful effect sizes for HD-tDCS and rTMS to be used for powering the next step, a Phase III multi-center trial.
Will I have to stop taking my current medications?
The trial requires that participants have been on stable doses of any psychotropic medications for the past 2 months, so you won't need to stop taking them if they have been stable.
What data supports the effectiveness of the treatment Neuromodulation + Cognitive Training for Traumatic Brain Injury?
Research shows that Attention Process Training (APT) can improve attention in individuals with brain injuries, including traumatic brain injury (TBI). Studies have demonstrated significant gains in attention and performance speed after using APT, with improvements remaining stable even after the training ended.12345
Is Attention Process Training (APT) safe for humans?
How is the Attention Process Training-3 treatment different from other treatments for traumatic brain injury?
Attention Process Training-3 (APT-3) is unique because it combines cognitive training with neuromodulation, which uses non-invasive techniques to stimulate the brain and enhance neuroplasticity (the brain's ability to reorganize itself). This approach is different from standard treatments that may not integrate these elements, potentially leading to improvements in attention and cognitive processing beyond conventional methods.15678
Research Team
Davin Quinn, MD
Principal Investigator
University of New Mexico
Eligibility Criteria
This trial is for Veterans aged 18-59 who've had a mild traumatic brain injury (TBI) with specific cognitive symptoms, and have been stable on any psychotropic meds for 2 months. They must not be pregnant, involved in TBI litigation, or have certain medical conditions like psychosis or recent substance dependence.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Baseline Testing
Participants undergo demographic, neuropsychological, behavioral, and quality of life testing, as well as MRI scanning
Treatment
Participants receive 16 sessions of APT-3 with concurrent rTMS, HD-tDCS, or sham stimulation
Post-treatment
Repeat of baseline tests including neuropsychological testing, symptom assessment, and MRI
Follow-up
Participants are monitored for safety and effectiveness after treatment at 3 and 6 months
Treatment Details
Interventions
- Attention Process Training
- HD-tDCS
- rTMS
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of New Mexico
Lead Sponsor
The Mind Research Network
Collaborator
New Mexico VA Healthcare System
Collaborator
Minneapolis Veterans Affairs Medical Center
Collaborator
University of Minnesota
Collaborator
New Mexico Veterans Affairs Health Care System
Collaborator
The United States Department of Defense USAMRDC
Collaborator